Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of CXCL13 detection agent in preparation of kit for predicting immunotherapy effect

An immunotherapy and detection agent technology, applied in the field of medicine, can solve the problems of lack of tumor-specific T cell markers and inability to make predictions

Active Publication Date: 2020-06-09
GUANGZHOU FINELMMUNE BIOTECHNOLOGY CO LTD
View PDF2 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, there is currently a lack of markers for tumor-specific T cells to predict

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of CXCL13 detection agent in preparation of kit for predicting immunotherapy effect
  • Application of CXCL13 detection agent in preparation of kit for predicting immunotherapy effect
  • Application of CXCL13 detection agent in preparation of kit for predicting immunotherapy effect

Examples

Experimental program
Comparison scheme
Effect test

Embodiment

[0031] Immunohistochemical staining of paraffin tumor tissue sections of melanoma patients with CXCL13 antibody can clearly detect the expression of CXCL13 protein, such as figure 1 As shown, the left picture shows the high expression of CXCL13, and the right picture shows the low expression of CXCL13.

[0032] About 60 melanoma patients who received PD-1 antibody treatment were selected, and the tumor sections before and after treatment were taken, and immunohistochemical staining was performed to detect CXCL13 and PD-L1, and the expression level and the patient's response to the antibody were analyzed. Correlation.

[0033] The specific steps of immunohistochemical staining to detect CXCL13 are as follows:

[0034] 1. Baked slices: slice the paraffin tumor tissues of melanoma patients into slices in a 60℃ oven for 1.5 hours.

[0035] 2. Deparaffinization: Place the sections in xylene for 10 minutes, replace the xylene, and then leave for another 10 minutes.

[0036] 3. Hydration: Put...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides application of a CXCL13 detection agent in preparation of a kit for predicting an immunotherapy effect. The CXCL13 detection agent is a reagent for detecting the expression level of CXCL13 in tumor specific T cells. The invention also provides a kit for predicting the immunotherapy effect. The kit comprises the CXCL13 detection agent. The invention also provides a method forpredicting the immunotherapy effect by detecting the expression level of CXCL13 in tumor specific T cells. The CXCL13 detection agent can be used for effectively and accurately detecting the expression level of CXCL13 and predicting the immunotherapy effect through the expression level.

Description

Technical field [0001] The invention belongs to the field of medicine, and specifically relates to the use of a CXCL13 detection agent in preparing a kit for predicting the effect of immunotherapy. Background technique [0002] Immunotherapy is a new and effective tumor treatment method. Immune checkpoint inhibitors represented by the PD-1 / PD-L1 antibody have achieved significant therapeutic effects in multiple clinical trials and have been approved for multiple indications. However, immunotherapy only shows a good effect in some patients. How to accurately find these effective patients is a difficult problem in clinical treatment. [0003] There are currently two main methods for predicting immune checkpoint inhibitors. One is to use immunohistochemistry to detect the level of PD-L1 protein expression in the tumor to predict the patient's effective rate. The expression of PD-L1 is regulated by INFG secreted by effector T cells. The high expression of PD-L1 indicates that there ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): G01N33/574
CPCG01N33/574G01N2333/7158
Inventor 周鹏辉刘振江何晶晶熊昕昕俞快董兴骏李硕付凌怡廖双叶
Owner GUANGZHOU FINELMMUNE BIOTECHNOLOGY CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com